Paracetamol

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Retrieved on: 
Tuesday, February 27, 2024

NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.

Key Points: 
  • NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.
  • A conference call will be held on March 5 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.

InventHelp Inventors Develop New Fever Pops for Children (AJD-203)

Retrieved on: 
Wednesday, February 14, 2024

Our flavorful design would help reduce fever and pain while also providing added hydration."

Key Points: 
  • Our flavorful design would help reduce fever and pain while also providing added hydration."
  • The patent-pending invention provides a new way to administer ibuprofen or acetaminophen to children.
  • The invention features a unique design that is easy to consume so it is ideal for parents with young children, hospitals, etc.
  • 22-AJD-203, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

Shriners Children's Doctor Alerts Parents of Overlooked Dangers of Microwave Soups and Noodles During National Burn Awareness Week

Retrieved on: 
Monday, February 5, 2024

Dr. David Greenhalgh, Chief of Burns at Shriners Children's Northern California, has spent more than 35 years working with pediatric burn patients.

Key Points: 
  • Dr. David Greenhalgh, Chief of Burns at Shriners Children's Northern California, has spent more than 35 years working with pediatric burn patients.
  • Now, the primary culprit is scalding injuries from simple items people forget are dangerous, such as hot liquids and microwave foods.
  • He says while convincing companies to change their packaging for products is a difficult and lengthy process, parents need to be aware of the dangers.
  • All three Shriners Children's burn care locations across the country are accredited by the American Burn Association (ABA) and the American College of Surgeons (ACS) as verified pediatric burn centers.

Hikma announces US launch of COMBOGESIC® IV

Retrieved on: 
Monday, February 5, 2024

LONDON, Feb. 5, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the launch of COMBOGESIC® IV (acetaminophen and ibuprofen) injection in the US.

Key Points: 
  • LONDON, Feb. 5, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the launch of COMBOGESIC® IV (acetaminophen and ibuprofen) injection in the US.
  • COMBOGESIC® IV is an intravenous, opioid-free pain relief medicine that is a combination of 1,000 mg of acetaminophen and 300 mg of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID).
  • In 2021, Hikma signed an exclusive license and distribution agreement with AFT Pharmaceuticals (AFT) for the commercialization of COMBOGESIC® IV in the US.
  • Under the trade name of MAXIGESIC® IV outside of the United States, COMBOGESIC® IV is licensed in over 100 countries and marketed in over 20 countries.

Public advisory - Pediatrix Acetaminophen Oral Solution for children: One lot recalled due to potential risk of overdose

Retrieved on: 
Wednesday, January 17, 2024

Children may be especially at risk of the effects of acetaminophen overdose given their small size and developing bodies.

Key Points: 
  • Children may be especially at risk of the effects of acetaminophen overdose given their small size and developing bodies.
  • Signs of acetaminophen overdose include nausea, vomiting, lethargy, sweating, loss of appetite and pain in the upper part of the abdomen or stomach.
  • Abdominal pain may be the first sign of liver damage and may not be apparent for 24 to 48 hours.
  • Given the limited scope of the recall, it will not have any impact on the general availability of children's acetaminophen products.

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

Retrieved on: 
Tuesday, January 9, 2024

Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades.

Key Points: 
  • Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades.
  • The entire medical research fraternity has prioritized cancer research in order to find new ways of treatment and analysis.
  • According to Nova one advisor, the global Oncology Cancer Drugs market was valued at USD 147.2 billion in 2021 and it is expected to hit around USD 289.2 billion by 2030 with a CAGR of 8.4% during the forecast period 2022 to 2030.
  • The article continued: “Drugs such as morphine, fentanyl, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and others are used extensively in treating cancer pain in patients with lung cancer, bone cancer, and other types of cancer.

Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024

Retrieved on: 
Monday, January 8, 2024

PALO ALTO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today issued a letter from Jaisim Shah, its Chief Executive Officer and President, to its stockholders highlighting the Company’s accomplishments in 2023 and its forward outlook for 2024.

Key Points: 
  • PALO ALTO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today issued a letter from Jaisim Shah, its Chief Executive Officer and President, to its stockholders highlighting the Company’s accomplishments in 2023 and its forward outlook for 2024.
  • Dear Scilex Holding Company Stockholders,
    I would like to express my deepest gratitude for your unwavering support, patience, and invaluable feedback throughout the transformative year in 2023.
  • As we continue to navigate the complexities of the pharmaceutical landscape, your role as stockholders in this journey is invaluable.
  • Despite the challenges that remain ahead, we are setting ambitious goals for the Company in 2024, including:
    Expected launch of Gloperba®.

United States MAXIGESIC IV (Paracetamol + Ibuprofen) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023

The "United States MAXIGESIC IV Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States MAXIGESIC IV Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about MAXIGESIC IV for acute pain in the United States.
  • A detailed picture of the MAXIGESIC IV for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the MAXIGESIC IV for acute pain.
  • This report provides a detailed market assessment of MAXIGESIC IV for acute pain in the United States.

Genexa Launches Clean Line of Kids’ Medicine in Whole Foods Market

Retrieved on: 
Tuesday, December 12, 2023

As the impending cold and flu season draws near, Genexa proudly announces the debut of its highly acclaimed clean, and effective, line of over-the-counter (OTC) children’s medicines at Whole Foods Market stores.

Key Points: 
  • As the impending cold and flu season draws near, Genexa proudly announces the debut of its highly acclaimed clean, and effective, line of over-the-counter (OTC) children’s medicines at Whole Foods Market stores.
  • And, we are also so proud to have our OTC products on shelf at Whole Foods,” said Genexa CEO David Johnson.
  • Genexa Kids’ Pain & Fever is an oral suspension for kids ages 2-11.
  • In addition to the children’s line, Whole Foods Market also carries Genexa’s adult pain relievers Acetaminophen Extra Strength and Acetaminophen PM.

SYNEVIT® Embraces Supplemental Synergy

Retrieved on: 
Thursday, November 30, 2023

FORT LAUDERDALE, Fla., Nov. 30, 2023 /PRNewswire/ -- The pharmaceutical world often focuses on specific ingredients. If an individual is in pain, they can take ibuprofen or acetaminophen. If they have digestive issues, they might take omeprazole. These highly targeted medical solutions have their place. However, the team at SYNEVIT® firmly believes that when an individual seeks natural, nutraceutical health and wellness support, they should think beyond single ingredients.

Key Points: 
  • However, the team at SYNEVIT® firmly believes that when an individual seeks natural, nutraceutical health and wellness support, they should think beyond single ingredients.
  • "Our motto is Technology in Synergy with Nature®," explains SYNEVIT® founder and CEO George Cvetkovski.
  • "Everything matters when creating nutraceutical formulas, including what ingredient you combine and the concentration of each one," Cvetkovski concludes.
  • We're always trying to upgrade our formulas to make sure all of the ingredients are working together to create synergistic results.